



August 25, 2022

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Conlon Danberg

**Re: HCW Biologics Inc.
Registration Statement on Form S-3
File No. 333-266991**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, HCW Biologics Inc. (the “**Company**”) hereby requests that the U.S. Securities and Exchange Commission (the “**Commission**”) take appropriate action to declare the above-referenced Registration Statement on Form S-3 to become effective on Friday, August 26, 2022, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter.

The Company hereby authorizes William L. Hughes of Orrick, Herrington & Sutcliffe LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.

The Company requests that it be notified of such effectiveness by a telephone call to William L. Hughes of Orrick, Herrington & Sutcliffe LLP at (415) 773-5720.

Very truly yours,

HCW BIOLOGICS INC.

By: /s/ Hing C. Wong

Name: Hing C. Wong, Ph.D.

Title: Chief Executive Officer and Director

cc: William L. Hughes, Orrick, Herrington & Sutcliffe LLP